Anticardiolipin antibody in vascular parkinsonism

Movement Disorders

Volumn 17, Issue 5, 2002, Pages 992-997

  Huang, Zhigao ^a   Jacewicz, Michael ^a   Pfeiffer, Ronald F ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Anticardiolipin antibody; Gait disorder; Vascular parkinsonism

Indexed keywords

CARDIOLIPIN ANTIBODY; IMMUNOGLOBULIN G; LEVODOPA; WARFARIN;

AGED; ANTICOAGULATION; BODY POSTURE; CEREBROVASCULAR DISEASE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; GAIT DISORDER; HUMAN; HYPERCOAGULABILITY; HYPERTENSION; IMAGING SYSTEM; MALE; MENTAL HEALTH; PARKINSONISM; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; STROKE; WHITE MATTER;

EID: 0036765121     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/mds.10219     Document Type: Review

References (46)

1. Critchley M. Arteriosclerotic parkinsonism. Brain 1929;52:23-82.
2. Thompson PD, Marsden CD. Gait disorder of subcortical arteriosclerotic encephalopathy: Binswanger's disease. Mov Disord 1987;2:1-8.
3. Friedman A, Kang UJ, Tatemichi TK, et al. A case of parkinsonism following striatal lacunar infarction. J Neurol Neurosurg Psychiatry 1986;49:1087-1088.
4. Murrow RW, Schweiger GD, Kepes JJ, Killer WC. Parkinsonism due to a basal ganglia lacunar state: clinicopathological correlation. Neurology 1990;40:897-900.
5. Pullicino P, Lichter D, Benedict R. Micrographia with cognitive dysfunction: "minimal" sequelae of a putaminal infarct. Mov Disord 1994;9:371-373.
6. Reider-Groswasser I, Bornstein NM, Korczyn AD. Parkinsonism in patients with lacunar infarcts of the basal ganglia. Eur Neurol 1995;35:46-49.
7. Ikeda K, Kotabe T, Kanbashi S, et al. Parkinsonism in lacunar infarcts of the basal ganglia. Eur Neurol 1996;36:248-249.
8. Zijlmans JCM, Thijssen HOM, Vogels OJM, et al. MRI in patients with suspected vascular parkinsonism. Neurology 1995;45:2183-2188.
9. Van Zagten M, Lodder J, Kessels F. Gait disorder and parkinsonian signs in patients with stroke related to small deep infarcts and white matter lesions. Mov Disord 1998;13:89-95.
10. Nutt JG, Marsden CD, Thompson PD. Human walking and higher-level gait disorders, particularly in the elderly. Neurology 1993; 43:268-279.
11. Elble RJ, Cousins R, Leffler K, Hughes L. Gait initiation by patients with lower-half parkinsonism. Brain 1996;119:1705-1716.
12. Fitzgerald PM, Jankovic J. Lower body parkinsonism: evidence for vascular etiology. Mov Disord 1989;4:249-260.
13. Bowie WEJ, Thompson JH, Pasacuzzi CA, Owen CA. Thrombosis in systemic lupus erythematosus despite circulating anticoagulants. J Clin Invest 1963;62:416-430.
14. Harris EN, Boey ML, Mackworth-Young CG, et al. Anticardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus. Lancet 1983;2: 1211-1214.
15. Hinton RC. Neurologic syndromes associated with antiphospholipid antibodies. Semin Thromb Hemost 1994;20:46-54.
16. Camerlingo M, Casto L, Censori B, et al. Anticardiolipin antibody in acute non-hemorrhagic stroke seen within six hours after onset. Acta Neurol Scand 1995;92:69-71.
17. Tuhrim S, Rand JH, Wu XX, et al. Elevated anticardiolipin antibody titer is a stroke risk factor in a multiethnic population independent of isotype or degree of positivity. Stroke 1999;8:1561-1565.
18. Zielinska J, Ryglewica D, Wierzchowska E, et al. Anticardiolipin antibodies are an independent risk factor for ischemic stroke. Neurol Res 1999;7:653-657.
19. Tanne D, D'Olhaberriague L, Schultz LR, et al. Anticardiolipin antibodies and their associations with cerebrovascular risk factors. Neurology 1999;52:1368-1373.
20. Fahn S, Elton RL, and members of the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Calne D, Goldstein M, eds. Recent developments in Parkinson's disease. Florham Park, NJ: MacMillan Healthcare Information; 1987:152-163.
21. Dyken ML, Wolf PA, Barnett HJM, et al. Risk factors in stroke: a statement for physicians by the subcommittee on risk factors and stroke of the stroke council. Stroke 1984;15:1105-1111.
22. Winikates J, Jankovic J. Clinical correlates of vascular parkinsonism. Arch Neurol 1999;56:98-102.
23. Fields RS, Toubbeh H, Searles RP, Bankhurst AD. The prevalence of anticardiolipin antibodies in a healthy elderly population and its association with antinuclear antibodies. J Rheumatol 1989;16:623-625.
24. Schmidt R, Auer-Grumbach P, Fazekas F, et al. Anticardiolipin antibodies in normal subjects. Neuropsychological correlates and MRI findings. Stroke 1995;26:749-754.
25. Rapizzi E, Ruffatti A, Tonello M, et al. Correction for age of anticardiolipin antibodies cut-off points. J Clin Lab Anal 2000;14: 87-90.
26. Kushner MJ. Prospective study of anticardiolipin antibodies in stroke. Stroke 1990;21:295-298.
27. Hess DC, Krauss J, Adams RJ, et al. Anticardiolipin antibodies: a study of frequency in TIA and stroke. Neurology 1991;41:525-528.
28. Brey RL, Hart RG, Sherman DG, Tegeler CH. Antiphospholipid antibodies and cerebral ischemia in young people. Neurology 1990;40:1190-1196.
29. Nagaraja D, Christopher R, Manjari T. Anticardiolipin antibodies in ischemic stroke in the young: Indian experience. J Neurol Sci 1997;150:137-142.
30. Toschi V, Motta A, Castelli C, et al. High prevalence of antiphosphatidylinositol antibodies in young patients with cerebral ischemia of undetermined cause. Stroke 1998;29:1759-1764.
31. Vaarala O, Palosuo T, Kleemola M, Aho K. Anticardiolipin response in acute infection. Clin Immunol Immunopathol 1986;41: 8-15.
32. Ameriso SF, Wong VLY, Quismorio FP, Fisher M. Immunohematologic characteristics of infection-associated cerebral infarction. Stroke 1991;22:1004-1009.
33. D'Olhaberriague L, Levine SR, Salowich-Palm L, et al. Specificity, isotype and titer distribution of anticardiolipin antibodies in CNS diseases. Neurology 1998;51:1376-1380.
34. The Antiphospholipid Antibodies in Stroke Study (APASS) Group. Anticardiolipin antibodies are an independent risk factor for first ischemic stroke. Neurology 1993;43:2069-2073.
35. Levine SR, Brey RL, Sawaya KL, et al. Recurrent stroke and thrombo-occlusive events in the antiphospholipid syndrome. Ann Neurol 1995;38:119-124.
36. Levine SR, Salowich-Palm L, Sawaya KL, et al. IgG anticardiolipin antibody titer >40 FPL and the risk of subsequent thrombo-occlusive events and death. A prospective cohort study. Stroke 1997;28:1660-1665.
37. Nakamura Y, Murakami M. Intravenous gammaglobulin in a hypothyroid patient with the antiphospholipid antibody syndrome. Ann Intern Med 1993;118:827-828.
38. Derksen RHW, Hasselaar P, Blokzijl L, et al. Lack of efficacy of plasma exchange in removing antiphospholipid antibodies. Lancet 1987;2:222.
39. Fulcher D, Stewart G, Exner T, et al. Plasma exchange and the anticardiolipin syndrome in pregnancy. Lancet 1989;2:171.
40. Frampton G, Cameron JS, Thom M, et al. Successful removal of antiphospholipid antibody during pregnancy using plasma exchange and low dose prednisone. Lancet 1987;2:1023-1024.
41. Derksen RH, Biesma D, Bouma BN, et al. Discordant effects of prednisone on anticardiolipin antibodies and the lupus anticoagulant. Arthritis Rheum 1986;29:1295-1296.
42. Nesher G, Ilany J, Rosemann D, et al. Valvular dysfunction in antiphospholipid syndrome: prevalence, clinical features, and treatment. Semin Arthritis Rheum 1997;27:27-35.
43. Simel DL, St. Clair EW, Adams J, et al. Correction of hypoprothrombinemia by immunosuppressive treatment of the lupus anticoagulant-hypoprothrombinemia syndrome. Am J Med 1987; 83:563-566.
44. Perez MC, Wilson WA, Scopelitis E. Cyclophosphamide use in a young woman with antiphospholipid antibodies and recurrent cerebrovascular accident. South Med J 1989;82:1421-1424.
45. Landi G, Galloni MV, Sabbadini MG, et al. Recurrent ischemic attacks in two young adults with lupus anticoagulant. Stroke 1983; 14:377-379.
46. Khamashta MA, Cuadrado MJ, Mujic F, et al. The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med 1995;332:993-997.